Xytis Begins Phase II Brain Injury Drug Trial
Posted on: Tuesday, 13 March 2007, 12:01 CDT
Xytis has enrolled the first patient in its phase II clinical trial with anatibant for the treatment of traumatic brain injury (TBI).
Phase I clinical trials with anatibant in healthy volunteers and patients with TBI demonstrated a favorable clinical safety, tolerability and pharmokinetic profile, according to the company. Xytis plans to enroll 400 patients with moderate to severe closed head TBI in 9 countries over the next 12 months.
Vincent Simmon, president and CEO of Xytis, said: "Patients with moderate to severe TBI will receive one of three doses of anatibant or placebo for five days. Endpoints for the trial include safety and tolerability, mortality as well as functional assessment at days six and 15 post-injury."
There are no therapeutics for TBI despite the fact that the CDC estimates that in the US there are 1.4 million TBI cases per year of which 50,000 patients die and 235,000 are hospitalized with moderate to severe TBI.
Source: Datamonitor
Related Articles
- New Data From Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting
- GPC Biotech Announces Data From Several Satraplatin Clinical Trials to Be Presented at ASCO Annual Meeting
- Gentium Announces the Data Safety Monitoring Board Review of the Phase III Trial of Defibrotide to Treat Patients With Severe Veno-Occlusive Disease
- Affymax Doses First Patient in the Phase 3 Clinical Program of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
- Spiration Inc. Announces Positive Results From Pilot Study of Treatment for Patients With Severe Emphysema at European Respiratory Society's Annual Congress
- University of Pittsburgh Clinical Study to Test Antibody Therapy for Patients With Severe Ulcerative Colitis
- Xolair (Omalizumab) Add-On Therapy Significantly Reduces Attacks in Patients With Severe Allergic Asthma
- A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*
- Corautus Genetics Inc. Announces Publication of Positive Gene Therapy Trial Results in Patients With Severe Angina
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds